Antivascular therapy of cancer metastasis.
Fidler
Isaiah J
IJ
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D001859:Bone Neoplasms / Q000517:prevention & control / Q000556:secondary; D018450:Disease Progression; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis / Q000473:pathology / Q000628:therapy*; D009369:Neoplasms / Q000098:blood supply* / Q000378:metabolism / Q000473:pathology*; D017239:Paclitaxel / Q000008:administration & dosage; D010879:Piperazines / Q000008:administration & dosage; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000473:pathology; D011743:Pyrimidines / Q000008:administration & dosage; D017978:Receptors, Growth Factor / Q000502:physiology; D017479:Receptors, Platelet-Derived Growth Factor / Q000378:metabolism
D001549:Benzamides; D006133:Growth Substances; D010879:Piperazines; D010982:Platelet-Derived Growth Factor; D011743:Pyrimidines; D017978:Receptors, Growth Factor; C075278:platelet-derived growth factor A; D000068877:Imatinib Mesylate; D017479:Receptors, Platelet-Derived Growth Factor; D017239:Paclitaxel